<!DOCTYPE  html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8"/><title>Microsoft Word - M Pharm PCI Syllabus all branches</title><meta name="author" content="HP"/><style type="text/css"> * {margin:0; padding:0; text-indent:0; }
 .s1 { color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 .s2 { color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 .p, p { color: black; font-family:"Lucida Sans Unicode", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; margin:0pt; }
 .s3 { color: black; font-family:"Lucida Sans Unicode", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6pt; }
 .a, a { color: black; font-family:"Lucida Sans Unicode", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 .s4 { color: black; font-family:"Lucida Sans Unicode", sans-serif; font-style: normal; font-weight: normal; text-decoration: underline; font-size: 9pt; }
 li {display: block; }
 #l1 {padding-left: 0pt;counter-reset: c1 2; }
 #l1> li>*:first-child:before {counter-increment: c1; content: counter(c1, decimal)" "; color: black; font-family:"Lucida Sans Unicode", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l1> li:first-child>*:first-child:before {counter-increment: c1 0;  }
 #l2 {padding-left: 0pt;counter-reset: c2 1; }
 #l2> li>*:first-child:before {counter-increment: c2; content: counter(c2, decimal)". "; color: black; font-family:"Lucida Sans Unicode", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l2> li:first-child>*:first-child:before {counter-increment: c2 0;  }
 li {display: block; }
 #l3 {padding-left: 0pt;counter-reset: d1 2; }
 #l3> li>*:first-child:before {counter-increment: d1; content: counter(d1, decimal)" "; color: black; font-family:"Lucida Sans Unicode", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l3> li:first-child>*:first-child:before {counter-increment: d1 0;  }
 #l4 {padding-left: 0pt;counter-reset: d2 1; }
 #l4> li>*:first-child:before {counter-increment: d2; content: counter(d2, decimal)". "; color: black; font-family:"Lucida Sans Unicode", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l4> li:first-child>*:first-child:before {counter-increment: d2 0;  }
 li {display: block; }
 #l5 {padding-left: 0pt;counter-reset: e1 2; }
 #l5> li>*:first-child:before {counter-increment: e1; content: counter(e1, decimal)" "; color: black; font-family:"Lucida Sans Unicode", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l5> li:first-child>*:first-child:before {counter-increment: e1 0;  }
 #l6 {padding-left: 0pt;counter-reset: e2 1; }
 #l6> li>*:first-child:before {counter-increment: e2; content: counter(e2, decimal)". "; color: black; font-family:"Lucida Sans Unicode", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l6> li:first-child>*:first-child:before {counter-increment: e2 0;  }
 li {display: block; }
 #l7 {padding-left: 0pt;counter-reset: f1 2; }
 #l7> li>*:first-child:before {counter-increment: f1; content: counter(f1, decimal)" "; color: black; font-family:"Lucida Sans Unicode", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l7> li:first-child>*:first-child:before {counter-increment: f1 0;  }
 #l8 {padding-left: 0pt;counter-reset: f2 1; }
 #l8> li>*:first-child:before {counter-increment: f2; content: counter(f2, decimal)". "; color: black; font-family:"Lucida Sans Unicode", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l8> li:first-child>*:first-child:before {counter-increment: f2 0;  }
 #l9 {padding-left: 0pt;counter-reset: f3 1; }
 #l9> li>*:first-child:before {counter-increment: f3; content: counter(f3, decimal)". "; color: black; font-family:"Lucida Sans Unicode", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l9> li:first-child>*:first-child:before {counter-increment: f3 0;  }
</style><link rel="sitemap" type="application/xml" title="Sitemap" href="/sitemap.xml"></head><body><p class="s1" style="padding-top: 3pt;padding-left: 73pt;text-indent: 0pt;text-align: center;">SEMESTER II</p><p class="s1" style="padding-top: 1pt;padding-left: 73pt;text-indent: 0pt;line-height: 115%;text-align: center;">REGULATORY ASPECTS OF DRUGS &amp; COSMETICS (MRA 201T)</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">Scope</p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 86%;text-align: justify;">This course is designed to impart the fundamental knowledge on the drug development process, regulatory requirements for approval of new drugs, drug products and cosmetics in regulated and semi-regulated countriesIt prepares the students to learn in detail on the regulatory requirements, documentation requirements, and registration procedures for marketing the drug products and cosmetics in regulated and semi-regulated countries.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">Objectives</p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 14pt;text-align: left;">Upon completion of the course, the student shall be able to know</p><p class="s2" style="padding-top: 1pt;padding-left: 41pt;text-indent: -18pt;line-height: 86%;text-align: left;">  <span class="p">process of drug discovery and development and generic product development</span></p><p class="s2" style="padding-left: 41pt;text-indent: -18pt;line-height: 89%;text-align: left;">  <span class="p">regulatory approval process and registration procedures for API and drug products in US, EU</span></p><p class="s2" style="padding-left: 23pt;text-indent: 0pt;line-height: 10pt;text-align: left;">  <span class="p">Cosmetics regulations in regulated and semi-regulated countries</span></p><p class="s2" style="padding-left: 23pt;text-indent: 0pt;line-height: 13pt;text-align: left;">  <span class="p">A comparative study of India with other global regulated markets</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">Theory                                 60 Hrs</p><p style="padding-top: 4pt;padding-left: 27pt;text-indent: -22pt;line-height: 85%;text-align: left;">1. <span class="s2">USA &amp; CANADA: </span>Organization structure and functions of FDA. Federal register and Code of Federal Regulations (CFR), History and evolution of United States Federal, Food, Drug and Cosmetic Act (FFDCA), Hatch Waxman act and Orange book, Purple book, Drug Master Files (DMF) system in US, Regulatory Approval Process for Investigational New Drug (IND), New Drug Application (NDA), Abbreviated New Drug Application (ANDA), Supplemental New Drug Application (SNDA); Regulatory requirements for Orphan drugs and Combination Products, Changes to an approved NDA / ANDA. Regulatory considerations for manufacturing, packaging and labeling of pharmaceuticals in USA. Legislation and regulations for import, manufacture, distribution and sale of cosmetics in USA and Canada.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><ol id="l1"><li data-list-text="2"><p class="s2" style="padding-left: 27pt;text-indent: -22pt;line-height: 82%;text-align: justify;">European Union &amp; Australia: <span class="p">Organization and structure of EMA &amp; EDQM, General guidelines, Active Substance Master Files (ASMF) system in EU, Content and approval process of IMPD, Marketing Authorization procedures in EU (Centralized procedure,</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p><p style="padding-top: 2pt;padding-left: 27pt;text-indent: 0pt;line-height: 86%;text-align: justify;">Decentralized procedure, Mutual recognition procedure and National Procedure). Regulatory considerations for manufacturing, packaging and labeling of pharmaceuticals in EU, Eudralex directives for human medicines, Variations &amp; extensions, Compliance of European Pharmacopoeia (CEP)/ Certificate of Suitability (CoS), Marketing Authorization (MA) transfers, Qualified Person (QP) in EU. Legislation and regulations for import, manufacture, distribution and sale of cosmetics in European Union &amp; Australia.</p></li><li data-list-text="3"><p class="s2" style="padding-left: 27pt;text-indent: -22pt;line-height: 86%;text-align: justify;">Japan: <span class="p">Organization of the PMDA, Pharmaceutical Laws and regulations, types of registration applications, DMF system in Japan, drug regulatory approval process, Regulatory considerations for manufacturing, packaging and labeling of pharmaceuticals in Japan, Post marketing surveillance in Japan. Legislation and regulations for import, manufacture, distribution and sale of cosmetics in Japan</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li data-list-text="4"><p class="s2" style="padding-left: 27pt;text-indent: -22pt;line-height: 86%;text-align: justify;">Emerging Market: <span class="p">Introduction, Countries covered, Study of the world map,study of various committees across the globe (ASEAN, APEC, EAC, GCC, PANDRH, SADC)</span></p><p class="s2" style="padding-left: 27pt;text-indent: 0pt;line-height: 87%;text-align: justify;">WHO: <span class="p">WHO, GMP, Regulatory Requirements for registration of drugs and post approval requirements in WHO through prequalification programme, Certificate of Pharmaceutical Product (CoPP) - General and Country Specific (South Africa, Egypt, Algeria and Morocco, Nigeria, Kenya and Botswana)</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li data-list-text="5"><p class="s2" style="padding-left: 28pt;text-indent: -22pt;line-height: 13pt;text-align: left;">Brazil, ASEAN, CIS and GCC Countries:</p><p class="s2" style="padding-left: 27pt;text-indent: 0pt;line-height: 12pt;text-align: justify;">ASIAN  Countries:  <span class="p">Introduction  to  ACTD,  Regulatory</span></p><p style="padding-left: 27pt;text-indent: 0pt;line-height: 86%;text-align: justify;">Requirements for registration of drugs and post approval requirements in China and South Korea &amp; Association of Southeast Asian Nations (ASEAN) Region i.e. Vietnam, Malaysia, Philippines, Singapore and Thailand.</p><p class="s2" style="padding-left: 27pt;text-indent: 0pt;line-height: 86%;text-align: justify;">CIS (Commonwealth Independent States): <span class="p">Regulatory pre- requisites related to Marketing authorization requirements for drugs and post approval requirements in CIS countries i.e. Russia, Kazakhstan and Ukraine GCC (Gulf Cooperation Council) for Arab states: Regulatory pre-requisites related to Marketing authorization requirements for drugs and post approval requirements in Saudi Arabia and UAE</span></p><p style="padding-left: 27pt;text-indent: 0pt;line-height: 87%;text-align: justify;">Legislation and regulations for import, manufacture, distribution and sale of cosmetics in Brazil, ASEAN, CIS and GCC Countries.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p><p class="s2" style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">REFERENCES :</p><ol id="l2"><li data-list-text="1."><p style="padding-top: 4pt;padding-left: 33pt;text-indent: -14pt;line-height: 76%;text-align: justify;">Generic Drug Product Development, Solid Oral Dosage forms, Leon Shargel and Isader Kaufer, Marcel Dekker series, Vol.143</p></li><li data-list-text="2."><p style="padding-left: 33pt;text-indent: -14pt;line-height: 75%;text-align: justify;">The Pharmaceutical Regulatory Process, Edited by Ira R. Berry Marcel Dekker Series, Vol.144</p></li><li data-list-text="3."><p style="padding-left: 33pt;text-indent: -14pt;line-height: 74%;text-align: justify;">The Pharmaceutical Regulatory Process, Second Edition Edited by Ira R. Berry and Robert P. Martin, Drugs and the Pharmaceutical Sciences, Vol.185 Informa Health care Publishers.</p></li><li data-list-text="4."><p style="padding-left: 33pt;text-indent: -14pt;line-height: 7pt;text-align: justify;">New Drug Approval Process: Accelerating Global Registrations By</p><p class="s3" style="padding-left: 42pt;text-indent: 0pt;line-height: 3pt;text-align: center;">th</p><p style="padding-left: 33pt;text-indent: 0pt;line-height: 65%;text-align: left;">Richard A Guarino, MD, 5 edition, Drugs and the Pharmaceutical Sciences, Vol.190.</p></li><li data-list-text="5."><p style="padding-left: 33pt;text-indent: -14pt;line-height: 75%;text-align: left;">Guidebook for drug regulatory submissions / Sandy Weinberg. By John Wiley &amp; Sons. Inc.</p></li><li data-list-text="6."><p style="padding-left: 33pt;text-indent: -14pt;line-height: 9pt;text-align: left;">Drugs: From Discovery to Approval, Second Edition By Rick Ng</p></li><li data-list-text="7."><p style="padding-top: 1pt;padding-left: 33pt;text-indent: -14pt;line-height: 75%;text-align: left;">New Drug Development: A Regulatory Overview, Eighth Edition By Mark Mathieu</p></li><li data-list-text="8."><p style="padding-left: 33pt;text-indent: -14pt;line-height: 75%;text-align: left;">Pharmaceutical Risk Management By Jeffrey E. Fetterman, Wayne L. Pines and Gary H. Slatko</p></li><li data-list-text="9."><p style="padding-left: 33pt;text-indent: -14pt;line-height: 75%;text-align: left;">Preparation and Maintenance of the IND Application in eCTD Format By William K. Sietsema</p></li><li data-list-text="10."><p style="padding-left: 33pt;text-indent: -13pt;line-height: 9pt;text-align: left;">Country Specific Guidelines from official websites.</p></li><li data-list-text="11."><p style="padding-top: 1pt;padding-left: 33pt;text-indent: -14pt;line-height: 75%;text-align: left;">http://www.who.int/medicines/areas/quality_safety/regulation_legislation/ ListMRAWebsites.pdf</p></li><li data-list-text="12."><p style="padding-left: 33pt;text-indent: -14pt;line-height: 10pt;text-align: left;">Roadmap to an ASEAN economic community Edited by Denis Hew.</p><p style="padding-left: 33pt;text-indent: 0pt;line-height: 10pt;text-align: left;">ISEAS Publications, Singapore 2005, ISBN981-230-347-2</p></li><li data-list-text="13."><p style="padding-left: 33pt;text-indent: -14pt;line-height: 75%;text-align: justify;">ASEAN, Rodolfo C. Severino, ISEAS Publications, Singapore 2005, ISBN 978-981-230-750-7</p></li><li data-list-text="14."><p style="padding-left: 33pt;text-indent: -14pt;line-height: 76%;text-align: justify;">Building a Future with Brics: The Next Decade for Offshoring, Mark Kobayashi-Hillary, Springer</p></li><li data-list-text="15."><p style="padding-left: 33pt;text-indent: -14pt;line-height: 75%;text-align: justify;">Outsourcing to India: The Offshore Advantage, Mark Kobayashi-Hillary, Springer Trade performance and Regional Integration of the CIS Countries, Lev Freinkman,</p></li><li data-list-text="16."><p style="padding-left: 33pt;text-indent: -13pt;line-height: 9pt;text-align: justify;">The world Bank, Washington, DC, ISBN: 0-8212-5896-0</p></li><li data-list-text="17."><p style="padding-top: 1pt;padding-left: 33pt;text-indent: -14pt;line-height: 75%;text-align: justify;">Global Pharmaceutical Policy: Ensuring Medicines for Tomorrow&#39;s World ByFrederick M. Abbott, Graham Dukes, Maurice Nelson Graham Dukes 139</p></li><li data-list-text="18."><p style="padding-left: 33pt;text-indent: -14pt;line-height: 75%;text-align: justify;">The Gulf Cooperation Council: A Rising Power and Lessons for ASEAN by Linda Low and Lorraine Carlos Salazar (Nov 22, 2010)</p></li><li data-list-text="19."><p style="padding-left: 33pt;text-indent: -14pt;line-height: 75%;text-align: justify;">Doing Business in the Asean Countries, Balbir Bhasin, Business Expert Press ISBN:13:978-1-60649-108-9</p></li><li data-list-text="20."><p style="padding-left: 33pt;text-indent: -14pt;line-height: 75%;text-align: justify;">Realizing the ASEAN Economic Community: A Comprehensive Assessment, Michael G Plummer (Editor), Chia Siow Yue (Editor), Instute of South east asian studies, Singapore</p></li></ol></li></ol><p class="s1" style="padding-top: 3pt;padding-left: 26pt;text-indent: 0pt;text-align: center;">REGULATORY ASPECTS OF HERBAL AND BIOLOGICALS</p><p class="s1" style="padding-top: 1pt;padding-left: 71pt;text-indent: 0pt;text-align: center;">(MRA 202T)</p><p class="s2" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">Scope</p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 86%;text-align: justify;">This course is designed to impart fundamental knowledge on Regulatory Requirements, Licensing and Registration, Regulation on Labelling of Biologics in India, USA and Europe</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 9pt;text-align: justify;">It prepares the students to learn in detail on Regulatory Requirements for</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: justify;">biologics, Vaccines and Blood Products</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">Objectives</p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Upon the completion of the course the student shall be able to :</p><p class="s2" style="padding-left: 23pt;text-indent: 0pt;line-height: 13pt;text-align: left;">  <span class="p">Know the regulatory Requirements for Biologics and Vaccines</span></p><p class="s2" style="padding-top: 1pt;padding-left: 41pt;text-indent: -18pt;line-height: 86%;text-align: left;">  <span class="p">Understand the regulation for newly developed biologics and biosimilars</span></p><p class="s2" style="padding-left: 41pt;text-indent: -18pt;line-height: 88%;text-align: left;">  <span class="p">Know the pre-clinical and clinical development considerations of biologics</span></p><p class="s2" style="padding-left: 23pt;text-indent: 0pt;line-height: 10pt;text-align: left;">  <span class="p">Understand the Regulatory Requirements of Blood and/or Its</span></p><p style="padding-left: 42pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Components Including Blood Products and label requirements</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">Theory                                 60 Hrs</p><p style="padding-top: 4pt;padding-left: 27pt;text-indent: -22pt;line-height: 86%;text-align: justify;">1. <span class="s2">India : </span>Introduction, Applicable Regulations and Guidelines , Principles for Development of Similar Biologics, Data Requirements for Preclinical Studies, Data Requirements for Clinical Trial Application, Data Requirements for Market Authorization Application, Post-Market Data for Similar Biologics, Pharmacovigilance. GMP and GDP.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><ol id="l3"><li data-list-text="2"><p class="s2" style="padding-left: 27pt;text-indent: -22pt;line-height: 86%;text-align: justify;">USA: <span class="p">Introduction to Biologics; biologics, biological and biosimilars, different biological products, difference between generic drug and biosimilars, laws, regulations and guidance on biologics/ biosimilars, development and approval of biologics and biosimilars (IND, PMA, BLA, NDA, 510(k), pre-clinical and clinical development considerations, advertising, labelling and packing of biologics</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li data-list-text="3"><p class="s2" style="padding-left: 27pt;text-indent: -22pt;line-height: 86%;text-align: justify;">European Union: <span class="p">Introduction to Biologics; directives, scientific guidelines and guidance related to biologics in EU, comparability/ biosimilarity assessment, Plasma master file, TSE/ BSE evaluation, development and regulatory approval of biologics (Investigational medicinal products and biosimilars), pre-clinical</span></p><p style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p><p style="padding-top: 2pt;padding-left: 27pt;text-indent: 0pt;line-height: 86%;text-align: left;">and clinical development considerations; stability, safety, advertising, labelling and packing of biologics in EU</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="4" height="14" alt="image" src="PRA_II_Sem_syllabus121021122842-5add8c51_files/Image_001.png"/></span></p></li><li data-list-text="4"><p class="s2" style="padding-top: 4pt;padding-left: 27pt;text-indent: -22pt;line-height: 86%;text-align: left;">Vaccine regulations in India, US and European Union: <span class="p">Clinical evaluation, Marketing authorisation, Registration or licensing, Quality assessment, Pharmacovigilance, Additional requirements Blood and Blood Products Regulations in India, US and European Union: Regulatory Requirements of Blood and/or Its Components Including  Blood  Products,  Label  Requirements,  ISBT (International Society of Blood Transfusion) and IHN (International Haemovigilence Network)</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li data-list-text="5"><p class="s2" style="padding-left: 27pt;text-indent: -22pt;line-height: 88%;text-align: left;">Herbal Products: <span class="p">Quality, safety and legislation for herbal products in India, USA and European Union.</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">REFERENCES</p><ol id="l4"><li data-list-text="1."><p style="padding-top: 3pt;padding-left: 26pt;text-indent: -14pt;line-height: 86%;text-align: left;">FDA Regulatory Affairs: A Guide for Prescription Drugs, Medical Devices, and Biologics, Douglas J. Pisano , David S. Mantus ; Informa ,2008</p></li><li data-list-text="2."><p style="padding-left: 26pt;text-indent: -14pt;line-height: 85%;text-align: left;">Biological Drug Products: Development and Strategies; Wei Wang , Manmohan Singh ; wiley ,2013</p></li><li data-list-text="3."><p style="padding-left: 26pt;text-indent: -14pt;line-height: 86%;text-align: left;">Development of Vaccines: From Discovery to Clinical Testing; Manmohan Singh , Indresh K. Srivastava ;Wiley, 2011</p></li><li data-list-text="4."><p style="padding-left: 26pt;text-indent: -14pt;line-height: 11pt;text-align: left;"><a href="http://www.who.int/biologicals/en">www.who.int/biologicals/en</a></p></li><li data-list-text="5."><p style="padding-top: 1pt;padding-left: 26pt;text-indent: -14pt;line-height: 85%;text-align: left;">www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInfo rmation/</p></li><li data-list-text="6."><p style="padding-left: 26pt;text-indent: -14pt;line-height: 11pt;text-align: left;"><a href="http://www.ihn-org.com/">www.ihn-org.com</a></p></li><li data-list-text="7."><p style="padding-left: 26pt;text-indent: -14pt;line-height: 12pt;text-align: left;"><a href="http://www.isbtweb.org/">www.isbtweb.org</a></p></li><li data-list-text="8."><p style="padding-top: 1pt;padding-left: 26pt;text-indent: -14pt;line-height: 85%;text-align: left;">Guidelines on Similar Biologics: Regulatory Requirements for Marketing Authorization in India</p></li><li data-list-text="9."><p style="padding-left: 26pt;text-indent: -14pt;line-height: 11pt;text-align: left;"><a href="http://www.cdsco.nic.in/">www.cdsco.nic.in</a></p></li><li data-list-text="10."><p style="padding-left: 12pt;text-indent: 0pt;text-align: left;"><a href="http://www.fda.gov/biologicsbloodVaccines/GuidanceCompliance" class="a" target="_blank">www.ema.europa.eu › scientific guidelines › Biologicals 11.</a>www.fda.gov/biologicsbloodVaccines/GuidanceCompliance  Regulatory</p></li></ol></li></ol><p style="padding-left: 26pt;text-indent: 0pt;line-height: 12pt;text-align: left;">Information (Biologics)</p><p class="s1" style="padding-top: 3pt;padding-left: 138pt;text-indent: -87pt;line-height: 113%;text-align: left;">REGULATORY ASPECTS OF MEDICAL DEVICES (MRA 203T)</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">Scope</p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 86%;text-align: justify;">This course is designed to impart the fundamental knowledge on the medical devices and <span class="s2">in vitro </span>diagnostics, basis of classification and product life cycle of medical devices, regulatory requirements for approval of medical devices in regulated countries like US, EU and Asian countries along with WHO regulations. It prepares the students to learn in detail on the harmonization initiatives, quality and ethical considerations, regulatory and documentation requirements for marketing medical devices and IVDs in regulated countries.</p><p class="s2" style="padding-top: 7pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">Objectives</p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 14pt;text-align: left;">Upon completion of the course, the student shall be able to know</p><p class="s2" style="padding-top: 1pt;padding-left: 41pt;text-indent: -18pt;line-height: 86%;text-align: left;">  <span class="p">basics of medical devices and IVDs, process of development, ethical and quality considerations</span></p><p class="s2" style="padding-left: 41pt;text-indent: -18pt;line-height: 88%;text-align: left;">  <span class="p">harmonization initiatives for approval and marketing of medical devices and IVDs</span></p><p class="s2" style="padding-left: 41pt;text-indent: -18pt;line-height: 88%;text-align: left;">  <span class="p">regulatory approval process for medical devices and IVDs in India, US, Canada, EU, Japan and ASEAN</span></p><p class="s2" style="padding-left: 23pt;text-indent: 0pt;line-height: 11pt;text-align: left;">  <span class="p">clinical evaluation and investigation of medical devices and IVDs</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">Theory                                  60 Hrs</p><p style="padding-top: 4pt;padding-left: 27pt;text-indent: -22pt;line-height: 86%;text-align: justify;">1.  <span class="s2">Medical  Devices:  </span>Introduction,  Definition,  Risk  based classification and Essential Principles of Medical Devices and IVDs. Differentiating medical devices IVDs and Combination Products from that of pharmaceuticals, History of Medical Device Regulation, Product Lifecycle of Medical Devices and Classification of Medical Devices.</p><p class="s2" style="padding-left: 27pt;text-indent: 0pt;line-height: 9pt;text-align: justify;">IMDRF/GHTF: <span class="p">Introduction, Organizational Structure, Purpose</span></p><p style="padding-left: 27pt;text-indent: 0pt;line-height: 86%;text-align: justify;">and Functions, Regulatory Guidelines, Working Groups, Summary Technical Document (STED), Global Medical Device Nomenclature (GMDN).</p><ol id="l5"><li data-list-text="2"><p class="s2" style="padding-left: 27pt;text-indent: -21pt;line-height: 86%;text-align: left;">Ethics: <span class="p">Clinical Investigation of Medical Devices, Clinical Investigation Plan for Medical Devices, Good Clinical Practice for Clinical Investigation of medical devices (ISO 14155:2011) </span>Quality: Quality System Regulations of Medical Devices: <span class="p">ISO 13485, Quality Risk  Management of Medical Devices: ISO 14971, Validation and Verification of Medical device, Adverse Event Reporting of Medical device</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p></li><li data-list-text="3"><p class="s2" style="padding-top: 3pt;padding-left: 27pt;text-indent: -22pt;line-height: 86%;text-align: justify;">USA: <span class="p">Introduction, Classification, Regulatory approval process for Medical Devices (510k) Premarket Notification,  Pre-Market Approval (PMA), Investigational Device Exemption (IDE) and </span>In vitro <span class="p">Diagnostics, Quality System Requirements 21 CFR Part 820, Labeling requirements 21 CFR Part 801, Post marketing surveillance of MD and Unique Device Identification (UDI). Basics of </span>In vitro <span class="p">diagnostics, classification and approval process.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li data-list-text="4"><p class="s2" style="padding-left: 27pt;text-indent: -22pt;line-height: 88%;text-align: justify;">European Union: <span class="p">Introduction, Classification, Regulatory approval process for Medical Devices</span></p><p style="padding-top: 1pt;padding-left: 27pt;text-indent: 0pt;line-height: 85%;text-align: justify;">(Medical Device Directive, Active Implantable Medical Device Directive) and <span class="s2">In vitro </span>Diagnostics (<span class="s2">In Vitro </span>Diagnostics Directive), CE certification process.</p><p style="padding-left: 27pt;text-indent: 0pt;line-height: 11pt;text-align: justify;">Basics of <span class="s2">In vitro </span>diagnostics, classification and approval process.</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li data-list-text="5"><p class="s2" style="padding-left: 27pt;text-indent: -22pt;line-height: 87%;text-align: justify;">ASEAN, China &amp; Japan: <span class="p">Medical Devices and IVDs, Regulatory registration procedures, Quality System requirements and clinical evaluation and investigation.</span></p><p style="padding-left: 30pt;text-indent: 0pt;line-height: 11pt;text-align: justify;">IMDRF study groups and guidance documents.</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">REFERENCES</p><ol id="l6"><li data-list-text="1."><p style="padding-top: 4pt;padding-left: 26pt;text-indent: -14pt;line-height: 85%;text-align: left;">FDA regulatory affairs: a guide for prescription drugs, medical devices, and biologics by Douglas J. Pisano, David Mantus.</p></li><li data-list-text="2."><p style="padding-left: 26pt;text-indent: -14pt;line-height: 10pt;text-align: left;">Medical Device Development: A Regulatory Overview by Jonathan S.</p><p style="padding-left: 26pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Kahan</p></li><li data-list-text="3."><p style="padding-top: 1pt;padding-left: 26pt;text-indent: -14pt;line-height: 85%;text-align: left;">Medical Product Regulatory Affairs: Pharmaceuticals, Diagnostics, Medical Devices by John J. Tobin and Gary Walsh</p></li><li data-list-text="4."><p style="padding-left: 26pt;text-indent: -14pt;line-height: 87%;text-align: left;">Compliance Handbook for Pharmaceuticals, Medical Devices and Biologics by Carmen Medina</p></li><li data-list-text="5."><p style="padding-left: 26pt;text-indent: -14pt;line-height: 12pt;text-align: left;">Country Specific Guidelines from official websites.</p></li></ol></li></ol><p class="s1" style="padding-top: 3pt;padding-left: 138pt;text-indent: -109pt;line-height: 112%;text-align: left;">REGULATORY ASPECTS OF FOOD &amp; NUTRACEUTICALS (MRA 204T)</p><p class="s2" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">Scope</p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 86%;text-align: justify;">This course is designed to impart the fundamental knowledge on Regulatory Requirements, Registration and Labeling Regulations of Nutraceuticals in India, USA and Europe.</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 9pt;text-align: left;">It prepares the students to learn in detail on Regulatory Aspects for</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">nutraceuticals and food supplements.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">Objectives</p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Upon completion of the course, the student shall be able to</p><p class="s2" style="padding-left: 23pt;text-indent: 0pt;line-height: 13pt;text-align: left;">  <span class="p">Know the regulatory Requirements for nutraceuticals</span></p><p class="s2" style="padding-top: 1pt;padding-left: 41pt;text-indent: -18pt;line-height: 86%;text-align: left;">  <span class="p">Understand the regulation for registration and labeling of nutraceuticals and food supplements in India, USA and Europe.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">Theory                                 60 Hrs</p><p style="padding-top: 3pt;padding-left: 27pt;text-indent: -22pt;line-height: 86%;text-align: justify;">1. <span class="s2">Nutraceuticals: </span>Introduction, History of Food and Nutraceutical Regulations, Meaning of Nutraceuticals, Dietary Supplements, Functional Foods, Medical Foods, Scope and Opportunities in Nutraceutical Market.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><ol id="l7"><li data-list-text="2"><p class="s2" style="padding-left: 27pt;text-indent: -22pt;line-height: 86%;text-align: justify;">Global Aspects: <span class="p">WHO guidelines on nutrition. NSF International: Its Role in the Dietary Supplements and Nutraceuticals Industries, NSF Certification, NSF Standards for Food And Dietary Supplements. Good Manufacturing Practices for Nutraceuticals.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li data-list-text="3"><p class="s2" style="padding-left: 27pt;text-indent: -22pt;line-height: 86%;text-align: justify;">India : <span class="p">Food Safety and Standards Act, Food Safety and Standards Authority of India: Organization and Functions, Regulations for import, manufacture and sale of nutraceutical products in India, Recommended Dietary Allowances (RDA) in India.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li data-list-text="4"><p class="s2" style="padding-left: 27pt;text-indent: -22pt;line-height: 86%;text-align: justify;">USA: <span class="p">US FDA Food Safety Modernization Act, Dietary Supplement Health and Education Act. U.S. regulations for manufacture and sale of nutraceuticals and dietary supplements, Labelling Requirements and Label Claims for Dietary Supplements, Recommended Dietary Allowances (RDA) in the U.S</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p></li><li data-list-text="5"><p class="s2" style="padding-top: 3pt;padding-left: 27pt;text-indent: -22pt;line-height: 86%;text-align: justify;">European Union: <span class="p">European Food Safety Authority (EFSA): Organization and Functions. EU Directives and regulations for manufacture and sale of nutraceuticals and dietary supplements. Nutrition labelling. European Regulation on Novel Foods and Novel Food Ingredients. Recommended Dietary Allowances (RDA) in Europe.</span></p><p style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">REFERENCES</p><ol id="l8"><li data-list-text="1."><p style="padding-top: 3pt;padding-left: 26pt;text-indent: -14pt;line-height: 85%;text-align: left;">Regulation of Functional Foods and Nutraceuticals: A Global Perspective by Clare M. Hasler (Wiley Online Library)</p></li><li data-list-text="2."><p style="padding-left: 26pt;text-indent: -14pt;line-height: 85%;text-align: left;">Nutraceutical and Functional Food Regulations in the United States and Around the World by Debasis Bagchi (Academic Press, Elsevier)</p></li><li data-list-text="3."><p style="padding-left: 26pt;text-indent: -14pt;line-height: 11pt;text-align: left;"><a href="http://www.who.int/publications/guidelines/nutrition/en/" class="s4" target="_blank">http://www.who.int/publications/guidelines/nutrition/en</a><a href="http://www.who.int/publications/guidelines/nutrition/en/" target="_blank">/</a></p></li><li data-list-text="4."><p style="padding-left: 26pt;text-indent: -14pt;line-height: 86%;text-align: left;">http://www.europarl.europa.eu/RegData/etudes/STUD/2015/536324/IPOL_ STU(2015)536324_EN.pdf</p></li><li data-list-text="5."><p style="padding-left: 26pt;text-indent: -14pt;line-height: 11pt;text-align: left;">Handbook of Nutraceuticals by Yashwant Pathak (CRC Press)</p></li><li data-list-text="6."><p style="padding-left: 26pt;text-indent: -14pt;line-height: 86%;text-align: left;">Food Regulation: Law, Science, Policy and Practice by Neal D. Fortin (Wiley)</p></li><li data-list-text="7."><p style="padding-left: 26pt;text-indent: -14pt;line-height: 12pt;text-align: left;">Country Specific Guidelines from official websites.</p><p class="s1" style="padding-top: 3pt;padding-left: 141pt;text-indent: -67pt;line-height: 113%;text-align: left;">REGULATORY AFFAIRS PRACTICAL - II (MRA 205P)</p><p style="text-indent: 0pt;text-align: left;"><br/></p><ol id="l9"><li data-list-text="1."><p style="padding-left: 41pt;text-indent: -18pt;line-height: 12pt;text-align: left;">Case studies on</p></li><li data-list-text="2."><p style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">Change Management/ Change control. Deviations</p></li><li data-list-text="3."><p style="padding-left: 41pt;text-indent: -18pt;line-height: 12pt;text-align: left;">Corrective &amp; Preventive Actions (CAPA)</p></li><li data-list-text="4."><p style="padding-left: 41pt;text-indent: -18pt;line-height: 12pt;text-align: left;">Documentation of raw materials analysis as per official monographs</p></li><li data-list-text="5."><p style="padding-left: 41pt;text-indent: -17pt;line-height: 12pt;text-align: left;">Preparation of audit checklist for various agencies</p></li><li data-list-text="6."><p style="padding-left: 41pt;text-indent: -17pt;line-height: 12pt;text-align: left;">Preparation of submission to FDA using eCTD software</p></li><li data-list-text="7."><p style="padding-left: 41pt;text-indent: -17pt;line-height: 12pt;text-align: left;">Preparation of submission to EMA using eCTD software</p></li><li data-list-text="8."><p style="padding-left: 41pt;text-indent: -17pt;line-height: 12pt;text-align: left;">Preparation of submission to MHRA using eCTD software</p></li><li data-list-text="9."><p style="padding-left: 41pt;text-indent: -17pt;line-height: 12pt;text-align: left;">Preparation of Biologics License Applications (BLA)</p></li><li data-list-text="10."><p style="padding-left: 41pt;text-indent: -17pt;line-height: 13pt;text-align: left;">Preparation of documents required for Vaccine Product Approval</p></li><li data-list-text="11."><p style="padding-left: 41pt;text-indent: -18pt;line-height: 87%;text-align: left;">Comparison of clinical trial application requirements of US, EU and India of Biologics</p></li><li data-list-text="12."><p style="padding-left: 41pt;text-indent: -17pt;line-height: 11pt;text-align: left;">Preparation of Checklist for Registration of Blood and Blood Products</p></li><li data-list-text="13."><p style="padding-left: 41pt;text-indent: -18pt;line-height: 87%;text-align: justify;">Registration requirement comparison study in 5 emerging markets (WHO) and preparing check list for market authorization</p></li><li data-list-text="14."><p style="padding-left: 41pt;text-indent: -18pt;line-height: 86%;text-align: justify;">Registration requirement comparison study in emerging markets (BRICS) and preparing check list for market authorization</p></li><li data-list-text="15."><p style="padding-left: 41pt;text-indent: -18pt;line-height: 85%;text-align: justify;">Registration requirement comparison study in emerging markets (China and South Korea) and preparing check list for market authorization</p></li><li data-list-text="16."><p style="padding-left: 41pt;text-indent: -18pt;line-height: 86%;text-align: justify;">Registration requirement comparison study in emerging markets (ASEAN) and preparing check list for market authorization</p></li><li data-list-text="17."><p style="padding-left: 41pt;text-indent: -18pt;line-height: 86%;text-align: justify;">Registration requirement comparison study in emerging markets (GCC) and preparing check list for market authorization</p></li><li data-list-text="18."><p style="padding-left: 41pt;text-indent: -17pt;line-height: 11pt;text-align: left;">Checklists for 510k and PMA for US market</p></li><li data-list-text="19."><p style="padding-left: 41pt;text-indent: -17pt;line-height: 12pt;text-align: left;">Checklist for CE marking for various classes of devices for EU</p></li><li data-list-text="20."><p style="padding-left: 41pt;text-indent: -17pt;line-height: 12pt;text-align: left;">STED Application for Class III Devices</p></li><li data-list-text="21."><p style="padding-left: 41pt;text-indent: -17pt;line-height: 12pt;text-align: left;">Audit Checklist for Medical Device Facility</p></li><li data-list-text="22."><p style="padding-left: 41pt;text-indent: -17pt;line-height: 13pt;text-align: left;">Clinical Investigation Plan for Medical Devices</p></li></ol></li></ol></li></ol></body></html>
